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Halcinonide is a high-potency topical glucocorticoid used for skin inflammation treatments that presents 
toxic systemic effects. A simple and quick analytical method to quantify the amount of halcinonide 
encapsulated into lipid nanoparticles, such as polymeric lipid-core nanoparticles and solid lipid 
nanoparticles, was developed and validated regarding the drug’s encapsulation efficiency and in vitro 
permeation. The development and validation of the analytical method were carried out using the high 
performance liquid chromatography with the UV detection at 239 nm. The validation parameters were 
specificity, linearity, precision and accuracy, limits of detection and quantitation, and robustness. The 
method presented an isocratic flow rate of 1.0 mL.min-1, a mobile phase methanol:water (85:15 v/v), and a 
retention time of 4.21 min. The method was validated according to international and national regulations. 
The halcinonide encapsulation efficiency in nanoparticles was greater than 99% and the in vitro drug 
permeation study showed that less than 9% of the drug permeated through the membrane, indicating a 
nanoparticle reservoir effect, which can reduce the halcinonide’s toxic systemic effects. These studies 
demonstrated the applicability of the developed and validated analytical method to quantify halcinonide 
in lipid nanoparticles.
Uniterms: Halcinonide/encapsulation efficiency. Halcinonide/quantification. Polymeric lipid-core 
nanoparticles. Solid lipid nanoparticles. Topical administration. Toxicity. High performance liquid 
chromatography/method validation.
INTRODUCTION
Topical corticosteroids or glucocorticoids are widely 
employed in dermatosis treatments due to their potent 
anti-inflammatory and anti-proliferative effects (Hengee 
et al., 2006; Guichard et al., 2015). However, the use of 
topical glucocorticoids can result in several local and 
adverse systemic effects, such as epidermis, dermis, or 
even subcutaneous tissue atrophy, resulting in irreversible 
stretch marks and in disorder of the wound-healing 
processes. Adverse systemic effects include body weight 
increase, Cushing’s syndrome, hypertension, diabetes 
mellitus, growth retardation, osteoporosis, peptic ulcer, 
and gastritis (Schacke, Docke, Asadullah, 2002; Senyigit, 
Ozer, 2012).
Halcinonide (C24H32ClFO5; MW: 454.96 Da) 
or (11β,16α)-21-chloro-9-fluoro-11-hydroxy-16, 
17-[(1-methylethylidene)bis(oxy)]pregn-4-ene-3, 
20-dione  (Figure  1)  i s  a  h igh-potency topica l 
corticosteroid, which is a hydrocortisone derivative and 
whose modifications alter its absorption, potency, and 
adverse effects. Halcinonide is classified as a Class II 
potency corticosteroid (Taheri, Feldman, 2012), whose 
characteristics include being a white crystalline powder, 
soluble in acetone and in chloroform, slightly soluble 
FIGURE 1 - Chemical structure of halcinonide.
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in alcohol and in ethyl ether, insoluble in water and in 
hexanes.
Halcinonide is administered by topical via. However, 
due to its high potency, it displays dose-dependent toxicity 
and local and systemic adverse effects. In order to reduce 
the drug toxicity and to improve its action, halcinonide 
can be encapsulated into nanostructured systems, such 
as nanoparticles, which promote a controlled release of 
the drug in specific sites (Schaffazick, Guterres, 2003; 
Senyigit, Ozer, 2012). Nanostructured systems, such 
as nanoparticles, are submicron size ranged-usually 
spherical-drug carriers. Lipid nanoparticles are widely 
used to carry lipophilic drugs and they are constituted 
by biocompatible and non-toxic lipids and may to be 
associated with polymers (Kelidari et al., 2015). They 
present advantages in the drug delivery control, such 
as good local tolerability, high encapsulation rate for 
lipophilic substances, and small particle size, which 
provide close contact with the stratum corneum. Moreover, 
they can create a film on the skin surface (Maia et al., 
2000).
In order to reduce the halcinonide toxicity in topical 
use, lipid nanoparticles, such as solid lipid nanoparticles 
(SLN) and polymeric lipid-core nanoparticles (LCN), 
were developed. SLNs are a colloidal carrier system 
for targeting drugs and are appropriate for use in cases 
of inflamed and damaged skin. They can favor drug 
penetration in the skin, maintaining a sustained release to 
avoid systemic absorption. They also reduce skin irritation 
due to their skin-targeting effect (Chen et al., 2006; Madan 
et al., 2014; Shah et al., 2015). LCNs are nanostructured 
devices in which a polymer wall surrounds the lipid 
core. They can stabilize the encapsulated substances and 
control the release of the drug to improve its effectiveness, 
acting as reservoir systems at the epidermis, and retaining 
themselves at the outermost layers of the skin (Jäger et al., 
2007; Venturini et al., 2011; Coradini et al., 2014; Fiel et 
al., 2014; Brum et al., 2015). 
The literature reports just one high performance 
liquid chromatography (HPLC) method that determines 
halcinonide from different sample types (Kirschbaum et al., 
1980). However, no study involving the quantification of 
halcinonide entrapped in lipid nanoparticles was submitted 
for the mandatory validation process. We developed and 
validated a simple, sensitive, and specific HPLC-UV 
method to determine the presence of halcinonide in lipid 
nanoparticles. Subsequently, this validated method was 
successfully used to quantify the amount of halcinonide 
encapsulated in these lipid nanostructured systems and to 
evaluate the in vitro drug permeation.
MATERIAL AND METHODS
Chemicals and reagents
Halcinonide 99,2% (Fagron, Anápolis, GO, Brazil), 
poly(ε-caprolactone) (Mw =10000-14000 g/mol, Sigma-
Aldrich, St. Louis, MO, USA), Span 60® (sorbitan 
stearate; Sigma Aldrich,St. Louis, MO, USA), Tween 
80® (polysorbate 80; Deleware, Porto Alegre, Brazil), 
capric/caprylic acid triglycerides (Focus Química, São 
Paulo, Brazil), stearic acid (Fagron, Anápolis, GO, Brazil) 
and acetone (Vetec, Rio de Janeiro, Brazil) were used to 
prepare the solid lipid nanoparticles (SLN) and polymeric 
lipid-core nanoparticles (LCN). HPLC-grade methanol 
was provided by Sigma-Aldrich (St. Louis, MO, USA). 
Water was purified in a Milli-Q Plus water purification 
system (Millipore, Bedford, MA, USA). All other reagents 
and solvents were of analytical grade.
Apparatus and chromatographic conditions
A Merck-Hitachi Lachrom HPLC (Tokyo, Japan) 
system, equipped with a D-7000 Interface, an L-7400 
UV detector module, a L-7100 quaternary pump, and an 
integral degasser, was used in the method development. 
A manual injector (Rheodyne) system, equipped with 
a 20-μL injector loop and a 100-μL syringe (Hamilton, 
Microliter 710), was used. Data acquisition, analysis, and 
reporting were performed using ChromQuest 5.0 (Thermo 
Fisher Scientific, San Jose, CA, USA).
Experiments were performed in the HPLC system 
described above using a GL Sciences C18 Inertsil® ODS3 
column (Torrance, CA, USA) of a 5-µm particle size, 
4.6-mm internal diameter, and 150-mm length and a GL 
Sciences C18 Inertsil® ODS3 guard cartridge system (10 
mm×4 mm, 5 μm) at 25±2 °C. The mobile phase, previously 
filtrated using a 0.45-µm PTFE membrane and degassed 
by sonication for 30 min, consisted of methanol and water 
(85:15 v/v) at an isocratic flow rate of 1.0 mL.min-1. The 
sample injection volume was of 20 µL. The halcinonide 
was monitored at 239 nm. The method run time was of 10 
minutes and all experiments were carried out in triplicate. 
Sample, standard solution, and system suitability 
preparation 
Halcinonide-loaded LCNs (LCN-HAL; 3.0 
mg.mL-1) were prepared with the interfacial deposition 
method described by Fiel et al. (2014). The organic phase, 
constituted of halcinonide, sorbitan stearate, capric/
caprylic acid triglycerides, and poly(ε-caprolactone), was 
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dissolved in acetone at 40 °C and injected into an aqueous 
phase containing Tween 80 under magnetic stirring. The 
suspension was submitted to vacuum and to acetone 
evaporation. All formulations were obtained in triplicate. 
Unloaded-LCN was also prepared as a negative control. 
Halcinonide-loaded SLNs (SLN-HAL; 3.0 mg.mL-1) 
were obtained by hot homogenization. A lipid phase, 
constituted by stearic acid and halcinonide, was heated 
at 70 °C. The aqueous phase, containing Tween 80, was 
heated at the same temperature and was added to the melted 
lipid under stirring. The emulsion was kept in the high 
shear homogenizer Ultra Turrax at 18,000 rpm for 10 min. 
Then, the nanoemulsion was immediately dispersed into 
cold distilled water (2–5 °C) stirred for 1 minute at 3,400 
rpm to solidify the nanoparticles (Ghadiri et al., 2012). All 
solid lipid nanoparticles were obtained in triplicate and the 
unloaded-SLN was also prepared as a negative control. 
Method development
The detection wavelength for the HPLC study 
was set at 239 nm after a spectrometric scanning. The 
chromatographic conditions were optimized for the 
halcinonide peak’s resolution, varying the mobile 
phase’s composition and proportion. Samples of different 
formulations were used to optimize the chromatographic 
conditions to resolve the halcinonide. These samples were 
filtered with a polytetrafluoroethylene (PTFE) membrane 
filter (Cromafil® Xtra, 0.45 μm × 25 mm, Macherey-
Nagel, Düren, Germany) before their injection into the 
HPLC system. An appropriate blank was injected before 
the analysis of every sample. The method was validated 
and used to determine halcinonide in the LCN and SLN 
nanoparticles, and to evaluate the in vitro drug permeation.
Method validation
To validate the analytical method, the guidelines 
established by the ICH, International Conference on 
the Harmonization of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use (2005) 
and the Brazilian regulation (ANVISA, 2003) were 
employed (Gomes et al., 2015; Klein, Longhini, Mello, 
2012). The method was validated for specificity, linearity, 
limit of detection (LOD), limit of quantitation (LOQ), 
accuracy, precision, and robustness.
Specificity
The specificity was determined by analyzing the 
chromatograms of unloaded nanoparticles in comparison 
with those obtained for both halcinonide-containing 
formulation nanoparticles (LCN-HAL and SLN-HAL), 
expecting the confirmation of no interference in the 
retention time and in the drug quantification due to 
formulation constituents (Gomes et al., 2015).
The nanoparticles were added in the mobile phase 
and kept under magnetic stirring during 24 h. Samples 
was assayed in the supernatant after a suitable dilution and 
filtration through a 0.45-µm PTFE membrane and injected 
into the HPLC system.
Linearity
The linearity was determined by the calculation 
of a regression line from the peak area’s plot versus 
the concentration of the working standard solutions 
prepared at five concentration levels (10.0; 15.0; 20.0; 
30.0 and 40.0 μg.mL-1) and it was evaluated by the least-
square regression analysis. A stock standard solution 
(500 μg.mL-1) was prepared daily by dissolving 5.0 mg 
of halcinonide in a 10-mL volumetric flask using the 
mobile phase (metanol:water 85:15, v/v). This solution 
was further diluted in the mobile phase to prepare the 
five different working standard solutions (ranging from 
10 to 40 μg.mL-1). The solutions were injected in the 
HPLC column in triplicate, keeping the injection volume 
constant (20 µL) and chromatograms were recorded. The 
standard deviation value for the slope, 𝑌-intercept, and 
other statistics of the calibration curve were calculated 
by linear regression and analysis of variance (ANOVA).
Limit of detection and limit of quantification 
The l imit  of  detection (LOD) and l imit  of 
quantification (LOQ) were calculated based on the 
standard deviation (SD) and on the slope (S) of the 
calibration curve according to the ICH (2005) and Fuster 
et al. (2015) by 3.3 SD/S and 10 DS/S to LOD and to LOQ 
respectively. 
Precision
The precision of the method was determined 
following the ICH requirements. It was evaluated at 
three levels: repeatability, intermediate precision, and 
reproducibility. The repeatability was investigated by 
testing six sample solutions at 25 μg.mL-1, evaluated 
in other two different days (reproducibility) and also 
prepared by two operators (intermediate precision). All 
analyzes were performed in sextuplicate. The results were 
reported in terms of relative standard deviation (RSD).
Accuracy
The accuracy was determined by the analysis 
of three intermediate points of the calibration curve 
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at different levels: low, intermediate, and high (17.5; 
25.0 and 35.0 μg.mL-1, respectively). To determine the 
recovery known concentration of the stock solution, it 
was prepared to achieve the final and theoretical drug 
concentrations. The accuracy value was determined by 
calculating the percent of halcinonide recovery for these 
three concentration levels and then determining the RSD 
(Klein, Longhini, Mello, 2012; Gomes et al., 2015).
Recovery
The recovery was determined in triplicate by the 
preparation of a halcinonide solution of 200 µg.mL-1, 
followed by the addition of a new halcinonide solution 
(500 µg.mL-1), obtaining a final concentration of 700 
µg.mL-1. The samples were diluted into 25 µg.mL-1 and 
the results were evaluated by the RSD. 
Robustness
In order to determine the robustness, experimental 
conditions were deliberately changed to verify the 
method’s reproducibility. It was evaluated by analyzing 
a halcinonide solution at a 25-μg.mL-1 varying flow rate 
(0.995 and 1.005 mL.min-1) and the composition of the 
mobile phase methanol:water (84:16 and 86:14 v/v). The 
samples were evaluated in triplicate for each variation. 
The chromatograms were recorded and compared with the 
previously reported chromatographic conditions. 
Evaluation of encapsulation efficiency
To assess the halcinonide’s encapsulation efficiency 
(EE) in lipid nanoparticles, 500 µl of samples were filtered 
using an Amicon® Ultra-0.5 mL 10 kDa filter device 
and centrifuged for 30 min at 40,000 rpm, according to 
Vijayakumar et al. (2016) and Zhang et al. (2016). The 
encapsulation efficiency was determined after the reading 
of the filtered samples in the HPLC, performed in triplicate 
and calculated using the equation (1):
In vitro drug permeation
In order to demonstrate the applicability of the 
validated method and the controlled drug delivery, 
the in vitro drug permeation of free halcinonide and 
of halcinonide encapsulated into LCN and SLN were 
evaluated. The skin permeation study was conducted 
in vertical diffusion cells, with a receiver compartment 
containing 12 ml and an available area of 1.77 cm2. 
Strat® M (Merck Millipore) synthetic membranes were 
used in the study due to their high similarity to human 
skin. The samples were individually incorporated into 
a 0.5% Natrosol gel to increase the nanosuspension’s 
viscosity, keeping the drug concentration at 0.1 % in all 
samples. The membrane was placed between the donor 
and receiver compartment of the vertical diffusion cells. 
1.0 g of sample-containing gel was added into the donor 
compartment and the system was kept under constant 
agitation at 37 °C. Considering the lipophilic nature of 
the sample, the receiver compartment was filled with 
isopropyl alcohol, ensuring the sink condition. Aliquots 
of 3.0 mL were withdrawn from the receiver fluid at 1, 2, 
4, 6, 8, 12, and 24 hours and the volume was replenished. 
The cumulative drug that permeated was quantified using 
the developed and validated HPLC analytical method. The 
study was performed in triplicate.
RESULTS AND DISCUSSION
Method development and validation
Previous tests were carried out in order to provide a 
quick and effective method to analyze halcinonide using 
the HPLC. The investigated chromatographic conditions 
were mainly related to the mobile phase composition. 
Initial runs included 60-minute exploratory runs using a 
mixture of methanol and water as a mobile phase, varying 
the proportion of methanol from % to 95%.
The mobile phase, composed by methanol:water 
85:15 (v/v), provided a symmetric peak for halcinonide 
with low retention time. The peak was detected at 4.21 
min (Figure 2), which is very suitable for routine analyses. 
In summary, methanol:water (85:15 v/v), a column 
temperature at 25 ± 2 °C, a sample injection volume of 
20 µL, an isocratic flow rate of 1.0 mL.min-1, a detector 
set at 239 nm, and a run time of 10 minutes were chosen 
as suitable chromatographic conditions for further 
procedures, including the method validation. 
The developed method proved itself specific for 
halcinonide quantification from LCN and SLN (Figure 
2), i.e. the peak related to the drug (tR = 4.21 min) did not 
appear in the inert nanoparticles, indicating no interference 
due to nanoparticle constituents in the halcinonide 
quantification.
A linear relationship between the peak area and 
the halcinonide concentration from 10.0 to 40.0 𝜇g.mL-1 
was observed (Figure 3) and the following general linear 
equation was obtained: y= -8299.2874 + 43639.9632x, 
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where y is the peak area and x is concentration at 
μg.mL-1. A suitable correlation coefficient (r=0.9994) 
that demonstrates that the method is linear with an r 
value of nearly 1.0 at the purposed range was recorded. 
According to the Analytical Methods Committee 
(AMC), a regression coefficient value near to 1.0 is not 
necessarily the outcome of a linear relationship and, 
consequently, the lack-of-fit test should be applied. 
This test evaluates the variance of the residual values. 
The ANOVA test to evaluate halcinonide linearity is 
presented in Table I. The F value for lack of fit was less 
than the tabulated F value for the 95% confidence level 
(α=0.05), and therefore, according to the ANOVA test, 
the linear regression showed no lack of fit (Gomes et al., 
2015; Klein, Longhini, Mello, 2012).
The lowest halcinonide concentration detected 
(LOD) and quantified (LOQ) with acceptable precision 
and accuracy was 0.04 and 0.14 μg.mL-1, respectively. 
These results prove that the chromatographic method is 
suitable enough to detect and quantify halcinonide at a 
concentration range of 10.0 to 40.0 µg.mL-1.
Precision, expressed as the RSD percentage of 
replicates, measures the relative errors of the method, 
as presented in Table II. The method developed for 
halcinonide quantification showed precision, because the 
RSD (%) values of all parameters were less than 5.0 %, 
as established by RE 899/2003 (ANVISA).
The accuracy of the method refers to the proximity 
between the mean of the measured values and their real 
concentrations values (ICH, 2005). The results (Table 
III) agree with Fuster et al. (2015) because the mean 
recovery values were near to 100 % and the RSD was at 
less than 2 %, thereby indicating a low variability and a 
strong agreement between the experimental and theoretical 
concentration values.
FIGURE 2 - Representative HPLC chromatograms obtained from halcinonide standard solution (25.0 μg.mL-1) in methanol:water 
and halcinonide-loaded and unloaded nanoparticles: LCN and SLN. Mobile phase: methanol:water (85:15 v/v); flow rate: 
1.0 mL/min; detection wavelength: 239 nm; column temperature: 25±2 °C; and injection volume: 20 µL. HAL: halcinonide. 
Retention time: 4.21 minutes.
TABLE I – ANOVA linearity results
SS DF MS F Ftab
Model 1.8581 x 108 1 1.8581 x 108 0.60 3.04
Residual 4.0503 x 109 13 3.1156 x 108 Linear
Lack of Fit 2.2397 x 108 3 0.7465 x 108 0.195117 2.72
Pure Error 3.8263 x 109 10 3.8263 x 108 No Lack of Fit
SS: sums of squares; DF: degrees of freedom; MS: mean squares; F: F value of the test; Ftab: fixed F value.
FIGURE 3 - Mean calibration curve obtained to halcinonide 
using working standard solutions at the concentration range 
from 10.0 to 40.0 µg.mL-1 (n=3).
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Results of recovery are shown in Table IV. The 
development method presented a recovery less than 5.0 
% of RSD, with a recovery percentage near to 100 %, 
in accordance to what was established by RE 899/2003 
(ANVISA).
The robustness of an analytical procedure measures 
its capacity to remain unaffected by small, but deliberate, 
variations in the method parameters, and provides an 
indication of its reliability during normal usage (ICH, 
2005). The method was considered robust because the 
RSD values were less than 1.54% for the drug content, 
as summarized in Table V, indicating that the deliberate 
variation of the method conditions had no significant 
effect on assay data or on chromatographic performance 
(Fontana, Bastos, Beck, 2010), not affecting the analysis 
of halcinonide in lipid nanoparticles.
Encapsulation efficiency
The drug content and encapsulation efficiency (EE) 
of halcinonide in lipid nanoparticles was carried out by 
the previously validated HPLC method and the results 
obtained are presented in Table VI. High percentages of 
entrapped drug were obtained for lipid nanoparticles in 
both types. All formulations presented suitable EE values 
greater than 99%. These values are mainly based on the 
poor aqueous solubility of halcinonide and on its high 
partition coefficient (log P=3.31), which leads to high 
drug load quantities in lipid nanoparticles. The current 
results are similar to the ones previously reported by 
Silva et al. (2015) on the EE of betamethasone (topical 
glucocorticoid) in nanoparticles using a similar method 
for quantification.
TABLE II - Repeatability, reproducibility and intermediate precision data of halcinonide analysis
Sample solution 
(25.0 µg.mL-1)
Experimental concentration  
(µg.mL-1 ± SD*)
Recovered  
(%)
RSD** 
(%)
Repetability (n=6) 25.90 ± 0.75 103.60 ± 2.99 2.88
Reproducibility (n=6)
Day 1 (morning) 25.61± 0.28 102.45 ± 1.14 1.09
Day 2 (morning) 25.10 ± 0.52 102.09 ± 4.46 4.37
Day 1 (afternoon) 25.23 ± 0.34 100.93 ± 1.36 1.35
Intermediate precision (n=6)
Analyst 1 25.87 ± 0.83 103.48 ± 3.33 3.21
Analyst 2 25.72 ± 0.33 102.90 ± 1.33 1.29
*SD: standard deviation; **RSD: relative standard deviation.
TABLE III - Accuracy assays for halcinonide analysis
Level of concentration
Theoretical 
concentration  
(µg.mL-1)
Experimental 
concentration  
(µg.mL-1 ± SD*)
Recovered  
(%)
RSD** 
(%)
Low 17.5 16.68 ± 0.25 95.31 ± 1.44 1.51
Medium 25.0 24.52 ± 0.18 98.06 ± 0.72 0.73
High 35.0 34.35 ± 0.30 98.14 ± 0.89 0.90
*SD: standard deviation; **RSD: relative standard deviation.
TABLE IV - Recovery assays for halcinonide analysis
Theoretical concentration 
(µg.mL-1)
Experimental concentration 
(µg.mL-1 ± SD*)
Recovered  
(%)
RSD** 
(%)
200 198.48 ± 6.18 99.24 ± 3.09 3.11
700 704.60 ± 22.69 100.65 ± 3.24 3.22
*SD: standard deviation; **RSD: relative standard deviation.
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In vitro permeation study
The permeation profile of pure halcinonide and 
halcinonide-loaded LCN and SLN are shown in Figure 4. 
An increase of pure halcinonide percentage in the 
receptor chambers with time was observed until 12 h. 
The permeation rates of pure halcinonide from Natrosol 
gel were about 18% and 50% during 6 and 24 hours, 
respectively. Since the synthetic membrane used has 
similarities to the human skin, halcinonide can permeate 
through the stratum corneum barrier due to its lipophilic 
character, reaching the dermis and being absorbed.
The halcinonide-loaded lipid nanoparticle profile 
presented no more than 9 % of permeated halcinonide 
and there was no skin permeation difference between the 
LCN and the SLN during 24 h (p>0.05, t-test). This result 
indicates that despite the nature of the lipid nanoparticles, 
which could promote the permeation of the drug, the 
reservoir effect promoted by the LCN and the SLN was 
essential to control the halcinonide release. 
With the purpose of obtaining drug quantification, 
both for EE and in vitro drug permeation, the validated 
method was successfully applied in the determination of 
halcinonide in lipid nanoparticles-LCN and SLN-and it 
can be considered an important tool for the quality control 
of these promising formulations.
CONCLUSION
A simple and effective HPLC method was developed 
and validated for the quantitative determination of 
halcinonide in lipid nanoparticles-LCN and SLN. This 
method was considered specific, linear, accurate, precise, 
and robust for a quick determination of halcinonide in 
lipid nanoparticles according to the ICH guideline and 
the Brazilian regulation (RE 899/2003). Furthermore, the 
TABLE V - Robustness for halcinonide analysis
Conditions Experimental concentration (µg.mL-1 ± SD*)
Recovered  
(%)
RSD** 
(%)
Flow rate
0.995 mL.min-1 25.89 ± 0.26 103.56 ± 1.05 1.00
1.005 mL.min-1 26.00 ± 0.41 104.03 ± 1.64 1.54
Mobile phase
84:16 26.25 ± 0.24 105.00 ± 0.95 0.90
86:14 26.48 ± 0.19 105.93 ± 0.75 0.70
*SD: standard deviation; **RSD: relative standard deviation.
TABLE VI - Halcinonide-loaded and encapsulation efficiency (EE) for polymeric lipid-core nanoparticles (LCN) and solid lipid 
nanoparticles (SLN)
Lipid nanoparticle sample
Theoretical concentration 
(µg.mL-1 ± SD*)
Experimental concentration 
(µg.mL-1 ± SD)
EE  
(% ± SD)
LCN-HAL 3000 2997.09 ± 1.14 99.90 ± 0.04
SLN-HAL 3000 2999.01 ± 0.10 99.96 ± 0.01
*SD: standard deviation. HAL: halcinonide.
FIGURE 4 - In vitro cumulative permeation-time profile of 
halcinonide and halcinonide-loaded lipid nanoparticles. HAL: 
halcinonide. *represent statistical different result; Student’s 
t-test (α=0.05).
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drug content and the encapsulation efficiency were quickly 
and suitably determined, as well as the halcinonide in vitro 
permeation profile, displaying a controlled drug release 
and indicating a possible reduction of halcinonide toxicity 
due to its nanoencapsulation.
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